Daniel R. Chevallard - Mar 17, 2022 Form 4 Insider Report for Viracta Therapeutics, Inc. (VIRX)

Role: CFO and COO
Signature: /s/ Shelly Vandertie, as Attorney-in-Fact
Stock symbol: VIRX
Transactions as of: Mar 17, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/18/2022, 05:35 PM
Previous filing: Mar 1, 2022
Next filing: May 27, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VIRX	Stock Option (Right to Buy)	Award	$0	+195K		$0.00	195K	Mar 17, 2022	Common Stock	195K	$3.04	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	One forty-eighth (1/48th) of the shares subject to the option shall vest on the date one month following February 23, 2022 (the "Vesting Commencement Date"), and one forty-eighth (1/48th) of the total shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each such date.

Content

One forty-eighth (1/48th) of the shares subject to the option shall vest on the date one month following February 23, 2022 (the "Vesting Commencement Date"), and one forty-eighth (1/48th) of the total shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each such date.